# A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of ALS-008176 in Healthy Japanese Adult Participants

> **NCT02478333** · PHASE1 · COMPLETED · sponsor: **Janssen Pharmaceutical K.K.** · enrollment: 24 (actual)

## Conditions studied

- Respiratory Syncytial Virus Infections

## Interventions

- **DRUG:** ALS-008176 (250 mg)
- **DRUG:** ALS-008176 (500 mg)
- **DRUG:** ALS-008176 (750 mg)
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT02478333
- **Lead sponsor:** Janssen Pharmaceutical K.K.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-05
- **Primary completion:** 2015-07
- **Final completion:** 2015-07
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2016-07-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02478333

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02478333, "A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of ALS-008176 in Healthy Japanese Adult Participants". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02478333. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*